Recommendations of Polish Myeloma Group concerning diagnosis and therapy of multiple myeloma and other plasmacytic dyscrasias for 2015
Abstract
New drugs introduced in recent years to the therapy of multiple myeloma patients resulted in better responses and prolongation of overall survival. Therapeutic regimens based on bortezomib, thalidomide and lenalidomide are recommended to most patients in first line therapy. Induction therapy should be accompanied with prolonged treatment composed of consolidation and maintenance. Besides the concept of longer treatment, it is recommended to start therapy in some patients earlier, taking into consideration biomarkers of active disease as well as transplantation procedure offered to older, fit patients. In this article we also described therapeutic recommendation for Waldenström macroglobulinemia and other plasmocytic dyscrasias.
Keywords: Multiple myelomaDiagnosisNew drugsTherapeutic considerations